Waldenstrom Macroglobulinemia Market Sees Surging Demand Across the 7MM Amid BTK Inhibitor Advancements
The Waldenstrom macroglobulinemia market is witnessing steady growth driven by advances in targeted therapies, particularly BTK inhibitors like IMBRUVICA and BRUKINSA. Rising awareness, improved diagnostic techniques, and increasing clinical trial activity are further propelling market expansion.
DelveInsight's Waldenstrom Macroglobulinemia Market Insights report includes a comprehensive understanding of current treatment practices, emerging Waldenstrom macroglobulinemia drugs, market share of individual therapies, and current and forecasted Waldenstrom macroglobulinemia market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Key Takeaways from the Waldenstrom Macroglobulinemia Market Report According to DelveInsight's analysis, the total Waldenstrom macroglobulinemia market size is expected to grow positively by 2034.
The United States accounts for the largest market size of Waldenstrom macroglobulinemia, in comparison to EU4 (Germany, Italy, France, and Spain) and the UK, and Japan.
Waldenström macroglobulinemia affects about 1 in 3.4 million American males and about half that number of American females. The incidence of waldenström macroglobulinemia is estimated to be about 5 per 1,000,000 people over the age of 50.
American males and about half that number of American females. The incidence of waldenström macroglobulinemia is estimated to be about people over the age of 50. Prominent companies, including Cellectar Biosciences, Merck Sharp & Dohme, BeiGene, Nurix Therapeutics, Ascentage Pharma, TransThera Biosciences, and others, are actively working on innovative Waldenstrom macroglobulinemia drugs.
and others, are actively working on innovative Waldenstrom macroglobulinemia drugs. Some of the key Waldenstrom macroglobulinemia therapies in the pipeline include Iopofosine, Nemtabrutinib, Sonrotoclax, NX-5948, Lisaftoclax, TT-01488 , and others. These novel Waldenstrom macroglobulinemia therapies are anticipated to enter the Waldenstrom macroglobulinemia market in the forecast period and are expected to change the market.
, and others. These novel Waldenstrom macroglobulinemia therapies are anticipated to enter the Waldenstrom macroglobulinemia market in the forecast period and are expected to change the market. In June 2025, Cellectar Biosciences announced that the US FDA granted Breakthrough Therapy Designation (BTD) for iopofosine I 131 in Waldenstrom macroglobulinemia.
announced that the US FDA granted Breakthrough Therapy Designation (BTD) for iopofosine I 131 in Waldenstrom macroglobulinemia. In June 2025, BeiGene showcased encouraging Phase I/II (CaDAnCe-101) results for BGB-16673 in waldenström macroglobulinemia at EHA 2025.
showcased encouraging Phase I/II (CaDAnCe-101) results for BGB-16673 in waldenström macroglobulinemia at EHA 2025. In March 2025, the US FDA granted orphan drug designation to bexobrutideg (NX-5948) for the treatment of Waldenstrom macroglobulinemia.
Discover which Waldenstrom macroglobulinemia medications are expected to grab the market share @ Waldenstrom Macroglobulinemia Market Report
Waldenstrom Macroglobulinemia Overview
Waldenstrom macroglobulinemia is a rare, slow-growing type of non-Hodgkin lymphoma characterized by the excessive production of abnormal white blood cells that secrete large amounts of a monoclonal IgM protein. These abnormal cells accumulate in the bone marrow and can interfere with the normal production of blood cells.
The exact cause of Waldenstrom macroglobulinemia is not fully understood, but it is believed to arise due to genetic mutations, most commonly in the MYD88 gene, and possibly immune system dysregulation. Risk factors may include age, male gender, family history, and certain inherited conditions.
Symptoms of Waldenstrom macroglobulinemia can vary significantly and often develop gradually. Common clinical signs include fatigue, weight loss, night sweats, and swollen lymph nodes. The excess IgM protein can cause hyperviscosity syndrome, leading to headaches, vision problems, dizziness, and bleeding issues. Some patients may also experience neuropathy, cold sensitivity, or enlargement of the spleen and liver.
Diagnosis typically involves a combination of blood tests, bone marrow biopsy, and molecular testing to identify MYD88 or CXCR4 mutations. Imaging may also be used to assess organ involvement. Early and accurate diagnosis is key to managing this indolent but complex hematologic malignancy.
Waldenstrom Macroglobulinemia Epidemiology Segmentation
The Waldenstrom macroglobulinemia epidemiology section provides insights into the historical and current Waldenstrom macroglobulinemia patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The Waldenstrom macroglobulinemia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Incident Cases of Waldenstrom Macroglobulinemia
Gender-specific Cases of Waldenstrom Macroglobulinemia
Age-specific Cases of Waldenstrom Macroglobulinemia
Gene Mutations in Waldenstrom Macroglobulinemia
Download the report to understand which factors are driving Waldenstrom macroglobulinemia epidemiology trends @ Waldenstrom Macroglobulinemia Treatment Algorithm
Waldenstrom Macroglobulinemia Treatment Market
Significant progress has been made in the treatment of Waldenström macroglobulinemia, a rare form of cancer, with therapies increasingly tailored to its unique clinical challenges. The Waldenström macroglobulinemia treatment landscape is primarily led by BTK inhibitors such as IMBRUVICA and BRUKINSA, alongside rituximab-based regimens and BCL-2 inhibitors like VENETOCLAX, which serve as complementary options. These targeted therapies have revolutionized clinical outcomes by extending progression-free survival and enhancing response rates, while maintaining manageable side effects.
BRUKINSA (zanubrutinib) from BeiGene represents a next-generation BTK inhibitor, engineered for improved selectivity and reduced off-target activity compared to earlier BTK inhibitors. It received U.S. FDA approval in 2021 for treating adults with Waldenström macroglobulinemia and has also been authorized by the EMA and other global regulatory bodies for use in this and other B-cell malignancies.
IMBRUVICA (ibrutinib), developed by Janssen and AbbVie, was the first BTK inhibitor to gain FDA approval in 2015 for adult patients with Waldenström macroglobulinemia. As a pioneering agent in its class, it transformed the treatment approach by disrupting B-cell signaling pathways that drive malignant cell growth. That same year, the European Commission also approved its use.
Rituximab remains the most commonly used monoclonal antibody for treating Waldenström macroglobulinemia. It works by binding to the CD20 protein found on the surface of lymphoma cells, triggering their destruction. Administered via intravenous infusion in clinical settings, rituximab may be used as a standalone therapy or in combination with chemotherapy, targeted treatments, or other agents.
Learn more about the Waldenstrom macroglobulinemia treatment options @ Waldenstrom Macroglobulinemia Treatment Guidelines
Waldenstrom Macroglobulinemia Emerging Drugs and Companies
The potential drugs in the pipeline include Iopofosine (Cellectar Biosciences), Nemtabrutinib (Merck Sharp & Dohme), Sonrotoclax (BeiGene), NX-5948 (Nurix Therapeutics), Lisaftoclax (Ascentage Pharma), TT-01488 (TransThera Biosciences), and others.
Iopofosine is a small-molecule Phospholipid Drug Conjugate (PDC) engineered to deliver iodine-131 directly to cancer cells in a targeted manner. It was recently assessed in the pivotal Phase II CLOVER-WaM study involving patients with relapsed/refractory Waldenstrom macroglobulinemia (R/R WM). The U.S. FDA has granted Fast Track Designation to iopofosine for use in patients with lymphoplasmacytic lymphoma (LPL) and Waldenstrom macroglobulinemia who have undergone at least two prior therapies. Furthermore, the drug has received Orphan Drug Designation (ODD) for LPL/WM.
In the European Union, the European Commission has granted ODD for relapsed/refractory multiple myeloma and WM, along with PRIME designation specifically for WM, acknowledging its potential to address significant unmet clinical needs. In June 2025, the FDA also awarded Breakthrough Therapy Designation (BTD) to iopofosine I-131 for treating R/R WM.
Nemtabrutinib is an experimental, reversible, non-covalent BTK inhibitor under investigation for its ability to block oncogenic B-cell receptor signaling. It is active against both wild-type BTK and BTK pathway mutations. Ongoing Phase II trials are evaluating its effectiveness in hematologic cancers, including chronic lymphocytic leukemia (CLL) and Waldenstrom macroglobulinemia. Unlike conventional BTK inhibitors, nemtabrutinib retains activity even against BTK proteins that have developed mutations.
Sonrotoclax is a BH3 mimetic designed to inhibit BCL2, a protein that enables cancer cell survival. By mimicking natural signals that promote cell death, sonrotoclax induces apoptosis in B-cell malignancies. Preclinical and early clinical studies have demonstrated that it is a potent and selective BCL2 inhibitor, characterized by a short half-life and no accumulation in the body. It has shown encouraging clinical results across multiple B-cell cancers, with over 1,300 patients treated globally. The U.S. FDA has granted Fast Track Designation to sonrotoclax for treating Waldenstrom macroglobulinemia.
The anticipated launch of these emerging Waldenstrom macroglobulinemia therapies are poised to transform the Waldenstrom macroglobulinemia market landscape in the coming years. As these cutting-edge Waldenstrom macroglobulinemia therapies continue to mature and gain regulatory approval, they are expected to reshape the Waldenstrom macroglobulinemia market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about new treatment for Waldenstrom macroglobulinemia, visit @ Waldenstrom Macroglobulinemia Management
Waldenstrom Macroglobulinemia Market Dynamics
The Waldenstrom macroglobulinemia market dynamics are anticipated to change in the coming years. The availability of targeted therapies such as BTK inhibitors (IMBRUVICA, BRUKINSA) and monoclonal antibodies (rituximab), along with the identification of MYD88 L265P and CXCR4 mutations, enables more personalized and effective treatment approaches, while emerging options like novel BTK inhibitors, CAR-T therapies, bispecific antibodies, and the development of new drug classes and combination regimens hold promise for significantly enhancing treatment outcomes.
Furthermore, many potential therapies are being investigated for the treatment of Waldenstrom macroglobulinemia, and it is safe to predict that the treatment space will significantly impact the Waldenstrom macroglobulinemia market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate is expected to drive the growth of the Waldenstrom macroglobulinemia market in the 7MM.
However, several factors may impede the growth of the Waldenstrom macroglobulinemia market. Targeted therapies like BTK inhibitors are often expensive, creating accessibility and reimbursement challenges, especially in lower-income countries, while resistance or intolerance to existing treatments like IMBRUVICA and BRUKINSA further necessitate alternative options, yet stringent approval processes and high clinical trial costs can significantly delay the launch of these new therapies.
Moreover, Waldenstrom macroglobulinemia treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the Waldenstrom macroglobulinemia market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the Waldenstrom macroglobulinemia market growth. Waldenstrom Macroglobulinemia Report Metrics Details Study Period 2020–2034 Waldenstrom Macroglobulinemia Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Key Waldenstrom Macroglobulinemia Companies Cellectar Biosciences, Merck Sharp & Dohme, BeiGene, Nurix Therapeutics, Ascentage Pharma, TransThera Biosciences, BioGene, Janssen, AbbVie, and others Key Waldenstrom Macroglobulinemia Therapies Iopofosine, Nemtabrutinib, Sonrotoclax, NX-5948, Lisaftoclax, TT-01488, BRUKINSA, IMBRUVICA, and others
Scope of the Waldenstrom Macroglobulinemia Market Report Waldenstrom Macroglobulinemia Therapeutic Assessment: Waldenstrom Macroglobulinemia current marketed and emerging therapies
Waldenstrom Macroglobulinemia current marketed and emerging therapies Waldenstrom Macroglobulinemia Market Dynamics: Conjoint Analysis of Emerging Waldenstrom Macroglobulinemia Drugs
Conjoint Analysis of Emerging Waldenstrom Macroglobulinemia Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Waldenstrom Macroglobulinemia Market Access and Reimbursement
Discover more about Waldenstrom macroglobulinemia drugs in development @ Waldenstrom Macroglobulinemia Clinical Trials
Table of Contents 1. Waldenstrom Macroglobulinemia Market Key Insights 2. Waldenstrom Macroglobulinemia Market Report Introduction 3. Waldenstrom Macroglobulinemia Market Overview at a Glance 4. Waldenstrom Macroglobulinemia Market Executive Summary 5. Disease Background and Overview 6. Waldenstrom Macroglobulinemia Treatment and Management 7. Waldenstrom Macroglobulinemia Epidemiology and Patient Population 8. Patient Journey 9. Waldenstrom Macroglobulinemia Marketed Drugs 10. Waldenstrom Macroglobulinemia Emerging Drugs 11. Seven Major Waldenstrom Macroglobulinemia Market Analysis 12. Waldenstrom Macroglobulinemia Market Outlook 13. Potential of Current and Emerging Therapies 14. KOL Views 15. Unmet Needs 16. SWOT Analysis
Related Reports
Waldenstrom Macroglobulinemia Pipeline
Waldenstrom Macroglobulinemia Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Waldenstrom macroglobulinemia companies, including BeiGene, Cellectar Biosciences, Inc., Nurix Therapeutics, Inc., VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Schrodinger, Inc., Loxo Oncology, Inc., Nkarta, Inc., Merck Sharp & Dohme LLC, ADC Therapeutics S.A., Bio-Path Holdings, Inc., Millennium Pharmaceuticals, Inc., Carna Biosciences, Inc., among others.
Non-Hodgkin's Lymphoma Market
Non-Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NHL companies, including AbbVie, Genmab, Novartis, Angiocrine Bioscience, Autolus, Zentera Therapeutics, Jiangsu Hengrui Medicine, among others.
Non-Hodgkin's Lymphoma Pipeline
Non-Hodgkin's Lymphoma Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key NHL companies, including Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc, Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd., Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc., among others.
Multiple Myeloma Market
Multiple Myeloma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple myeloma companies, including Sanofi, Karyopharm Therapeutics, AbbVie, Takeda Pharmaceutical, Celgene, Bristol-Myers Squibb, RAPA Therapeutics, Pfizer, Array Biopharma, Cellectar Biosciences, BioLineRx, Celgene, Aduro Biotech, ExCellThera, Janssen Pharmaceutical, Precision BioSciences, Takeda, Glenmark (Ichnos Sciences SA), Poseida Therapeutics, Molecular Partners AG, Chipscreen Biosciences, AbbVie, Genentech (Roche), Janssen Biotech, Nanjing Legend Biotech, Merck Sharp & Dohme Corp., among others.
Diffuse Large B-cell Lymphoma Market
Diffuse Large B-cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key DLBCL companies, including Roche (Genentech), Biogen, Nektar Therapeutics, Merck, Allogene Therapeutics, Miltenyi Biomedicine, AstraZeneca, BioVaxys, ImmunoVaccine Technologies, Cellectar Biosciences, Galapagos, Novartis, Lyell, ImmPACT Bio, Pfizer, Kartos Therapeutics, 2seventy bio, Regeneron Pharmaceuticals, BeiGene, Ranok Therapeutics, Constellation Pharmaceuticals, Genmab, IDP Discovery Pharma S.L., Immunitas Therapeutics, Monte Rosa Therapeutics, SymBio Pharmaceuticals, AVM Biotechnology, Autolus Therapeutics, Kymera Therapeutics, Otsuka Pharmaceutical, Caribou Biosciences, Adicet Bio, Gilead Sciences, Xynomic Pharmaceuticals, Amgen, among others.
DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.
Other Business Pharmaceutical Consulting Services
Healthcare Conference Coverage
Pipeline Assessment
Healthcare Licensing Services
Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
26 minutes ago
- The Hill
Schumer blasts Trump's EU deal: ‘It's fake!'
Senate Minority Leader Chuck Schumer (D-N.Y.) blasted the trade deal negotiated between the United States and the European Union over the weekend, calling it 'fake.' The trade deal sets tariffs on European goods at 15 percent, half the rate that Trump had previously threatened on the continent. In exchange, the EU has pledged to buy $750 billion in American energy over the next three years. 'Trump would have you believe it's the biggest deal ever,' Schumer complained. 'Europe has admitted that this agreement isn't legally binding, and they have no control over whether these investments even happen.' While Europe is presumably avoiding a trade war with the U.S., several leading figures condemned the deal. French Prime Minister Francois Bayrou called Sunday a 'dark day' in a post on X. Schumer compared the agreement to Trump's deal with Japan, where the U.S. has imposed a 15 percent tariff in exchange for $550 billion in Japanese investments in American sectors. It is not clear what those exact investments would entail. The deal with Europe was reached days before Trump's postured deadline of Aug. 1, when his threatened levies are generally scheduled to take place. American trade representatives have fanned across the globe to attempt to make deals with countries as the president has continued dialing tariffs up and down. Schumer was also among the Democratic senators who sent a letter to Commerce Secretary Howard Lutnick Monday criticizing the administration's reversal on allowing certain high-powered computer chips to be sold to China.
New York Post
an hour ago
- New York Post
Trump's trade wins shock the experts — who are blind to business reality
If America is in the midst of a trade war, the question we have to ask is: Are we tired of winning yet? President 'Donald Trump reaps $50bn tariff haul as world 'chickens out,'' reads the Financial Times headline. 'Only China and Canada have retaliated against US president's tariff war,' its subhead adds. 'In the Trump-dominated global economy, the US gets plenty but gives nothing in return,' reads a rueful post on X from Axios — another publication with an upmarket readership — promoting an article titled, 'Trump trade deals prove access to the US still matters above all else.' Populist publications have a different take on Trump's spate of trade victories. 'Trump's trade deal bloc — let's call it The Free World — now encompasses 57% of global GDP . . . 40% of total global trade in goods,' and '18% of the world's population,' according to Breitbart's John Carney. The president has only been in office six months, and his tariffs haven't even been in place that long, but already the results are undeniable. At a time when there otherwise seems to be no end to federal deficits, Trump's trade policy put the federal government in the black for the month of June, with a $27 billion surplus — and, as it happens, about $27 billion in tariff revenue. It's one thing that Trump so often surprises political opponents who underestimate him at election time and can't understand the root of his appeal. What's more remarkable is Trump seems to defy the very laws of economics — or rather, the law as laid down by economists. Other social sciences have lately lost credibility thanks to a 'republication crisis' that shows how the results reported in leading journals of psychology and other fields all too often fail to be repeated when experiments are conducted anew and data are re-examined. Every morning, the NY POSTcast offers a deep dive into the headlines with the Post's signature mix of politics, business, pop culture, true crime and everything in between. Subscribe here! Will the economics profession — whose mainstream is fervently in favor of free trade and is convinced tariffs are madness — face a similar reckoning for getting this test wrong? Trump can do things the economists say can't be done because he approaches trade the way he conducts his real-estate business: It's a negotiation, and leverage is what counts. Precisely because the United States has such an enormous trade deficit with the rest of the world — amounting to more than $918 billion in 2024 — other nations depend on access to our market as an outlet for their goods. The size and wealth of the American consumer base is unmatchable, and countries that get cut off from it can't easily make up the difference by selling more goods and services somewhere else. Whole industries in Europe and Asia would collapse without access to the American consumer. Trump is willing to give them access — for a price. Instead of using punitive tariffs to exclude foreign goods altogether, Trump is willing to strike a deal with anyone to allow goods to be sold in America at a price that makes the trade worthwhile for Americans and foreign companies alike. The hitch: The deal must be on terms favorable for American workers and industry. The president's arrangement with the European Union levies a 15% tariff on most EU goods — but that's peanuts compared to the 30% Trump was threatening if Europe didn't cooperate. The deal calls for new European investments of $600 billion in America, as well as for EU members to buy more energy and military equipment from us. The 15% tariff is higher than what European producers were paying before Trump returned to the White House — high enough that American producers will get some protective advantage, but not so high that foreign companies won't be able to compete. Start your day with all you need to know Morning Report delivers the latest news, videos, photos and more. Thanks for signing up! Enter your email address Please provide a valid email address. By clicking above you agree to the Terms of Use and Privacy Policy. Never miss a story. Check out more newsletters That's crucial because competition is what keeps prices down for American consumers. Foreign firms can't easily 'pass on' a tax on their goods — which is what a tariff is — to the Americans who buy their products when those same Americans can choose from domestic producers instead. The modest protection a 15% tariff affords gives more investors at home a reason to put their capital into American companies — which is good for our workforce and consumers alike. It means more jobs and more goods; more money in Americans' pockets and more stock on the shelves, which keeps prices down. There's risk in all this, but the upside opportunity is much greater, as entrepreneurs here and abroad recognize. For the Europeans, it's a no-brainer: The American market is so rife with profit possibilities that a 15% access fee is a very modest cost of doing business. American businesses should recognize their opportunity as well — they're native to a market the entire world is desperate to be in, and they should use that advantage to the fullest, investing at home and making the sales that foreign firms are so eager to make here. In this trade war, all Americans are winning — except, perhaps, the overeducated prisoners of the Ivory Tower. Daniel McCarthy is the editor of Modern Age: A Conservative Review and editor-at-large of The American Conservative.
The Hill
2 hours ago
- The Hill
Five takeaways as Trump's trip to Scotland nears conclusion
President Trump will conclude his four-day trip to his ancestral homeland of Scotland on Tuesday. The final engagement on Trump's official schedule before his return is the opening of a new golf course, in memory of his late mother, in Aberdeen, on the east coast of Scotland. That's a fitting conclusion to a trip that has included some Trump brand promotion in addition to official business. But it's not as if the news has stopped during Trump's Scottish sojourn. Here are the five biggest takeaways. U.S. gets the better of a trade deal with the European Union The announcement of a trade deal with the EU was plainly the biggest substantive moment from the trip. Trump and European Commission President Ursula von der Leyen put the finishing touches to the agreement on Sunday, meeting at Trump's other Scottish golf course at Turnberry. There was still some vagueness around specifics but the basic gist of the deal is that European imports to the U.S. will mostly be tariffed at 15 percent. From the EU's perspective, the main selling point in such a deal is that it saves the bloc from the 30 percent tariff rate that would have kicked in this Friday in the absence of a new agreement. However, the 15 percent tariff rate is higher than the 10 percent United Kingdom Prime Minister Keir Starmer helped negotiate for his nation in May; higher than was previously the case; and largely unleavened by any major concessions from the American side. It's no surprise, then, that the deal has got an adverse reaction from many commentators in Europe, who accuse their leaders of selling the continent short. But Trump doesn't care much about that. He can claim a victory here – so long as his tariff regime overall doesn't set off the inflationary cycle that many economists have long predicted. Hunger in Gaza creates pressure on Trump The deepening catastrophe in Gaza produced some unpredictable moments – but not much clarity – from Trump during his trip. Malnutrition among Gaza's population of 2.1 million people has worsened precipitously, after Israel initially cut off aid and food to the strip for more than two months beginning in March. More recently, small amounts of aid have been allowed to enter, though humanitarian groups consider those volumes to be woefully insufficient. According to a World Health Organization statement released on Sunday, there have been 63 malnutrition-related deaths in Gaza in July, including 24 deaths of children under five. Images of skeletal children have sparked fresh outrage in much of the world aimed at Israel and its prime minister, Benjamin Netanyahu. As recently as Sunday, Trump didn't display much urgency on the topic, placing blame on Hamas and complaining that the U.S. had not been shown sufficient gratitude for aid it had already supplied to Gaza. By Monday, there was at least a tonal difference from the president – even though he repeated his comments about a supposed lack of gratitude. Asked whether he agreed with an assertion from Netanyahu that there was no starvation in Gaza, Trump replied, 'I don't know. I mean, based on television, I would say not particularly, because those children look very hungry.' Trump also said, 'That's real starvation. I see it and you can't fake that.' British government sources told the liberal-leaning Guardian newspaper that Starmer had 'privately pressed Trump on Gaza during the trip.' Trump also promised the U.S. would set up food centers in Gaza, though details were sparse. The key question, of course, is whether anything substantive will change in American policy toward Israel. On Ukraine, Trump directs more ire at Putin One of the most unexpected developments of recent months has been Trump shifting toward a harder line on Russia. That idea seemed fanciful back in late February when Trump and Vice President Vance berated Ukrainian President Volodymyr Zelensky in the Oval Office. But Trump has grown frustrated with Russian President Vladimir Putin's stubbornness in continuing to pursue the war begun with his invasion three and a half years ago. Trump declared himself 'disappointed in President Putin' during remarks on Monday. He also suggested he would tighten a deadline for peace negotiations to '10 or 12 days.' Putin has not seemed overly concerned with Trump's deadlines previously but the remarks were nonetheless an indicator of the president's growing frustration with the Kremlin. The Epstein saga proves inescapable Trump has proven unable to put the controversy over Jeffrey Epstein behind him – and his Scottish trip did not change that. Just as before, it was words and actions from Trump and his allies that, at least in part, kept the matter in the headlines. On Monday, Trump suggested that his falling-out with Epstein two decades ago had its roots in the disgraced financier repeatedly hiring staff away. 'He stole people that worked for me,' Trump said. This explanation had not previously been offered as a reason why Trump had broken off contact with Epstein – a move that came before Epstein was charged with any criminal offense. Previous interpretations leaned on the idea that Epstein had engaged in some kind of inappropriate behavior that had come to Trump's attention, or that the two men had become estranged because of a competitive battle over real estate. Separately, Monday also saw reporting that Trump's legal team wants media mogul Rupert Murdoch deposed as soon as possible in his lawsuit for defamation against the Wall Street Journal. The legal filing raised the issue of 'health issues' for Murdoch, who is 94. Trump is suing the Journal over a report that a letter bearing his name was included in an album to marking Epstein's 50th birthday in 2003. Trump says the letter is fake. In any event, now that Reps. Thomas Massie (R-Ky.) and Ro Khanna (D-Calif.) are mounting a bipartisan bid to force the Department of Justice to give up more documentation about Epstein, Trump will need to recognize that the issue won't be going anywhere for a while. Plenty of publicity for the golf courses Critics have long lamented overlaps between Trump's political activities and his business interests. They will further irked by the Scotland trip, which was at least as much about golfing as about political business. But Trump seems sure to appreciate the massive amount of free publicity he has just got bestowed upon his Scottish courses.
